Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
Mohamad Moussa,1 Athanasios Papatsoris,2 Mohamed Abou Chakra,1 Athanasios Dellis2,3 1Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon; 2 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University...
Main Authors: | Moussa M, Papatsoris A, Abou Chakra M, Dellis A |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2021-02-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/profile-of-enfortumab-vedotin-in-the-treatment-of-urothelial-carcinoma-peer-reviewed-article-DDDT |
Similar Items
-
Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
by: Jain RK, et al.
Published: (2020-09-01) -
Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
by: Thibodeau A, et al.
Published: (2021-10-01) -
Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
by: Paul V. Viscuse, et al.
Published: (2021-03-01) -
Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
by: Allison S. Dobry, MD, et al.
Published: (2021-08-01) -
A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
by: Andrea Francis, BS, et al.
Published: (2021-01-01)